{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:23:55Z","timestamp":1773707035602,"version":"3.50.1"},"reference-count":29,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2023,12,31]]},"DOI":"10.1080\/13696998.2023.2165366","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T07:54:07Z","timestamp":1673942047000},"page":"200-207","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of abobotulinumtoxinA versus onabotulinumtoxinA for the treatment of refractory neurogenic detrusor overactivity: a systematic review and indirect treatment comparison"],"prefix":"10.1080","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4551-514X","authenticated-orcid":false,"given":"Francisco","family":"Cruz","sequence":"first","affiliation":[{"name":"Hospital de S\u00e3o Jo\u00e3o, Porto, Portugal"},{"name":"i3S Institute of Health Research and Innovation, University of Porto, Porto, Portugal"},{"name":"Faculty of Medicine, University of Porto, Porto, Portugal"}]},{"given":"Natalya","family":"Danchenko","sequence":"additional","affiliation":[{"name":"Ipsen, Boulogne-Billancourt, France"}]},{"given":"Kyle","family":"Fahrbach","sequence":"additional","affiliation":[{"name":"Evidera, Waltham, MA, USA"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0265-9338","authenticated-orcid":false,"given":"Andreas","family":"Freitag","sequence":"additional","affiliation":[{"name":"Evidera, London, UK"}]},{"given":"Jialu","family":"Tarpey","sequence":"additional","affiliation":[{"name":"Evidera, Waltham, MA, USA"}]},{"given":"John","family":"Whalen","sequence":"additional","affiliation":[{"name":"Ipsen, Slough, UK"}]}],"member":"301","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"key":"e_1_3_4_2_1","first-page":"S205","article-title":"Managed care aspects of managing neurogenic bladder\/neurogenic detrusor overactivity","volume":"19","author":"Cardarelli WJ.","year":"2013","unstructured":"Cardarelli WJ. Managed care aspects of managing neurogenic bladder\/neurogenic detrusor overactivity. Am J Manag Care. 2013;19(10 Suppl):S205\u2013S208.","journal-title":"Am J Manag Care"},{"issue":"6","key":"e_1_3_4_3_1","first-page":"404","article-title":"Evaluation, treatment, and surveillance of neurogenic detrusor overactivity in spinal cord injury patients","volume":"12","author":"Alsulihem A","year":"2019","unstructured":"Alsulihem A, Corcos J. Evaluation, treatment, and surveillance of neurogenic detrusor overactivity in spinal cord injury patients. Neuroimmunol Neuroinflammation. 2019;12(6):404\u2013412.","journal-title":"Neuroimmunol Neuroinflammation"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.7224\/1537-2073.2012-031"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sc.2013.19"},{"key":"e_1_3_4_6_1","unstructured":"Ellsworth PI Coyle PK Esquenazi A et\u00a0al. Consensus statement on neurogenic detrusor overactivity: multiple sclerosis and spinal cord injury. 2012. Corpus ID: 59115883."},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/RRU.S29644"},{"key":"e_1_3_4_8_1","doi-asserted-by":"crossref","unstructured":"National Institute for Health and Care Excellence (NICE). Urinary incontinence and pelvic organ prolapse in women: management. NICE guideline published April 2 2019. https:\/\/www.nice.org.uk\/guidance\/ng123\/resources\/urinary-incontinence-and-pelvic-organ-prolapse-in-women-management-pdf-66141657205189.","DOI":"10.1111\/bju.14763"},{"key":"e_1_3_4_9_1","unstructured":"National Institute for Health and Care Excellence (NICE). Lower urinary tract symptoms in men: management. NICE guideline published May 23 2010. https:\/\/www.nice.org.uk\/guidance\/cg97\/resources\/lower-urinary-tract-symptoms-in-men-management-pdf-975754394053"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22445"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004397-200404430-00014"},{"issue":"4","key":"e_1_3_4_12_1","first-page":"198","article-title":"Botulinum toxin for the treatment of idiopathic and neurogenic overactive bladder: state of the art","volume":"8","author":"Nitti VW.","year":"2006","unstructured":"Nitti VW. Botulinum toxin for the treatment of idiopathic and neurogenic overactive bladder: state of the art. Rev Urol. 2006;8(4):198\u2013208.","journal-title":"Rev Urol"},{"key":"e_1_3_4_13_1","unstructured":"U.S. Food and Drug Administration [Internet]. Prescribing information BOTOX (onabotulinumtoxinA). 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/103000s5236lbl.pdf"},{"key":"e_1_3_4_14_1","unstructured":"Ipsen [Internet]. Ipsen receives positive opinion in Europe for Dysport\u00ae in the management of urinary incontinence in adults with neurogenic detrusor overactivity due to multiple sclerosis or spinal cord injury. 2022. https:\/\/www.ipsen.com\/press-releases\/ipsen-receives-positive-opinion-in-europe-for-dysport-in-the-management-of-urinary-incontinence-in-adults-with-neurogenic-detrusor-overactivity-due-to-multiple-sclerosis-or-spinal-cord-injury\/"},{"key":"e_1_3_4_15_1","unstructured":"ClinicalTrials.gov [Internet]. Dysport\u00ae treatment of urinary incontinence in adults subjects with neurogenic detrusor overactivity (NDO) due to spinal cord injury or multiple sclerosis \u2013 study 1 (CONTENT1). 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02660138"},{"key":"e_1_3_4_16_1","unstructured":"ClinicalTrials.gov [Internet]. Dysport\u00ae treatment of urinary incontinence in adults subjects with neurogenic detrusor overactivity (NDO) due to spinal cord injury or multiple sclerosis \u2013 study 2 (CONTENT2). 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02660359"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(21)00418-8"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.01.011"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.04.002"},{"key":"e_1_3_4_20_1","doi-asserted-by":"crossref","unstructured":"Page MJ McKenzie JE Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_4_21_1","unstructured":"Higgins JPT Thomas J Chandler J et al. editors. Cochrane Handbook for Systematic Reviews of Interventions. 2021. Accessed November 29 2021."},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20195"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(97)00049-8"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v036.i03"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-012-0984-0"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.07.002"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.01.125"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000162035.73977.1c"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.06.007"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000002798"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2023.2165366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T10:20:09Z","timestamp":1701944409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2023.2165366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,14]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,31]]}},"alternative-id":["10.1080\/13696998.2023.2165366"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2023.2165366","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-10-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}